BioXcel Therapeutics (BTAI) CFO Richard Steinhart sold 6,845 shares for $7,426.
The sale occurred on May 20, 2026 at a weighted average price of $1.085.
The sale was conducted under a Rule 10b5-1 plan to cover taxes from RSU vesting.
Steinhart now directly holds 26,300 shares.












